Abstract
Imatinib mesylate induces major or complete cytogenetic responses in the majority of patients with chronic myeloid leukemia (CML) in chronic phase. However, 15-40% of patients develop neutropenia and/or thrombocytopenia that makes it necessary to reduce the dosage or to interrupt treatment. Patients with recurrent cytopenias may be less likely to obtain cytogenetic responses. We speculated that low doses of granulocyte colony-stimulating factor (G-CSF) in conjunction with imatinib might offer clinical benefit. Eleven patients with CML in chronic (n=9) or accelerated (n=2) phase who could not tolerate 300 mg/day and had no cytogenetic response after 6 months of imatinib treatment received G-CSF in combination with imatinib. Ten of the 11 patients could then tolerate doses of imatinib equal to or greater than 300 mg/day and 7 patients achieved major (n=6) or complete (n=1) cytogenetic responses. We conclude that G-CSF reverses the hematologic toxicity of imatinib and may thereby increase the proportion of cytogenetic responses.
| Original language | English |
|---|---|
| Pages (from-to) | 227-229 |
| Number of pages | 3 |
| Journal | Haematologica |
| Volume | 88 |
| Issue number | 2 |
| Publication status | Published - Feb 1 2003 |
Fingerprint
Keywords
- G-CSF cytopenia
- Imatinib
ASJC Scopus subject areas
- Hematology
Cite this
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. / Marin, David; Marktel, Sarah; Foot, Nicola; Bua, Marco; Olavarria, Eduardo; Galdman, John M.; Apperley, Jane F.
In: Haematologica, Vol. 88, No. 2, 01.02.2003, p. 227-229.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate
AU - Marin, David
AU - Marktel, Sarah
AU - Foot, Nicola
AU - Bua, Marco
AU - Olavarria, Eduardo
AU - Galdman, John M.
AU - Apperley, Jane F.
PY - 2003/2/1
Y1 - 2003/2/1
N2 - Imatinib mesylate induces major or complete cytogenetic responses in the majority of patients with chronic myeloid leukemia (CML) in chronic phase. However, 15-40% of patients develop neutropenia and/or thrombocytopenia that makes it necessary to reduce the dosage or to interrupt treatment. Patients with recurrent cytopenias may be less likely to obtain cytogenetic responses. We speculated that low doses of granulocyte colony-stimulating factor (G-CSF) in conjunction with imatinib might offer clinical benefit. Eleven patients with CML in chronic (n=9) or accelerated (n=2) phase who could not tolerate 300 mg/day and had no cytogenetic response after 6 months of imatinib treatment received G-CSF in combination with imatinib. Ten of the 11 patients could then tolerate doses of imatinib equal to or greater than 300 mg/day and 7 patients achieved major (n=6) or complete (n=1) cytogenetic responses. We conclude that G-CSF reverses the hematologic toxicity of imatinib and may thereby increase the proportion of cytogenetic responses.
AB - Imatinib mesylate induces major or complete cytogenetic responses in the majority of patients with chronic myeloid leukemia (CML) in chronic phase. However, 15-40% of patients develop neutropenia and/or thrombocytopenia that makes it necessary to reduce the dosage or to interrupt treatment. Patients with recurrent cytopenias may be less likely to obtain cytogenetic responses. We speculated that low doses of granulocyte colony-stimulating factor (G-CSF) in conjunction with imatinib might offer clinical benefit. Eleven patients with CML in chronic (n=9) or accelerated (n=2) phase who could not tolerate 300 mg/day and had no cytogenetic response after 6 months of imatinib treatment received G-CSF in combination with imatinib. Ten of the 11 patients could then tolerate doses of imatinib equal to or greater than 300 mg/day and 7 patients achieved major (n=6) or complete (n=1) cytogenetic responses. We conclude that G-CSF reverses the hematologic toxicity of imatinib and may thereby increase the proportion of cytogenetic responses.
KW - G-CSF cytopenia
KW - Imatinib
UR - http://www.scopus.com/inward/record.url?scp=0038460326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038460326&partnerID=8YFLogxK
M3 - Article
C2 - 12604417
AN - SCOPUS:0038460326
VL - 88
SP - 227
EP - 229
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 2
ER -